Last reviewed · How we verify
Metastatic malignant melanoma
Approved treatments
- Dtic-Dome · Bayer
- Tafinlar · Novartis
Tafinlar blocks the activity of a mutated protein called BRAF that is involved in cancer cell growth. - Yervoy · Bristol-Myers Squibb
Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells. - Mektovi · Pfizer
Mektovi works by blocking a specific enzyme called MEK1, which is involved in sending signals that promote cancer cell growth. - Pembrolizuma · Memorial Sloan Kettering Cancer Center
- Yervoy · Bristol-Myers Squibb
- Cotellic · Roche
Cotellic works by blocking the activity of two proteins, BRAF and MEK, which are involved in the growth and spread of cancer cells. - Mektovi · Pfizer
Mektovi works by blocking the MEK1 enzyme, which is a key player in the signaling pathway that promotes cancer cell growth. - Braftovi · Pfizer
Braftovi works by blocking the activity of a specific protein called BRAF that is involved in cancer cell growth. - Proleukin · Chiron
- Mekinist · Novartis
Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells. - Opdivo · Bristol-Myers Squibb
Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells. - Proleukin · University of Minnesota
Clinical guidelines
- FDA label — 1L
BRAFTOVI in combination with binimetinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. - FDA label — 1L
BRAFTOVI in combination with binimetinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. - FDA label — 1L
BRAFTOVI in combination with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastatic malignant melanoma patent landscape — cliff calendar, originator estates, attackable patents
- Metastatic malignant melanoma treatment landscape brief
- Metastatic malignant melanoma treatment updates RSS
Frequently asked questions about Metastatic malignant melanoma
What drugs treat Metastatic malignant melanoma?
Tracked treatments include Dtic-Dome, Tafinlar, Yervoy, Mektovi, Pembrolizuma, Cotellic, Braftovi, Proleukin.
What is the treatment for Metastatic malignant melanoma?
Standard treatment for Metastatic malignant melanoma includes Dtic-Dome, Tafinlar, Yervoy, Mektovi, Pembrolizuma. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Metastatic malignant melanoma?
FDA label publishes guidelines for Metastatic malignant melanoma. 3 guideline references tracked.
Related
- Treatment landscape: Metastatic malignant melanoma patent cliff · Metastatic malignant melanoma CI report
- Treatment: Dtic-Dome · Bayer
- Treatment: Tafinlar · Novartis
- Treatment: Yervoy · Bristol-Myers Squibb
- Treatment: Mektovi · Pfizer
- Treatment: Pembrolizuma · Memorial Sloan Kettering Cancer Center
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing